Japan Digital Therapeutics Market

Japan Digital Therapeutics Market Insights Forecasts to 2035

• The Japan Digital Therapeutics Market Size Was Estimated at USD 285.2 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 18.03% from 2025 to 2035

The Japan Digital Therapeutics Market Size is Expected to Reach USD 1765.8Million by 2035

According to a Research Report Published by Decision Advisior & Consulting, the Japan Digital Therapeutics Market size is anticipated to reach USD 1765.8million by 2035, growing at a CAGR of 18.03% from 2025 to 2035. The Japan digital therapeutics market is driven by increasing prevalence of chronic and lifestyle-related diseases, rising adoption of smartphone- and web-based therapy solutions, and strong demand for personalized disease management platforms. Growth is also supported by integration with remote monitoring systems, cloud-based patient engagement platforms, and increasing clinical validation of digital therapeutic programs for conditions such as diabetes, obesity, and mental health disorders.

Market Overview

The Japanese digital therapeutics market refers to software-driven therapeutic interventions that deliver evidence-based treatment for medical conditions, either as a standalone therapy or in conjunction with conventional treatment. These solutions include apps, mobile platforms, cloud-based software, and remote monitoring systems designed for chronic disease management, mental health support, behavioral therapy, and lifestyle modification. The market is characterized by growing adoption of digital health solutions, increasing use of patient-centered care platforms, and rising integration of remote monitoring and AI-based clinical decision tools. Key drivers include the need for cost-effective healthcare solutions, increasing chronic disease prevalence, and widespread smartphone penetration. Major trends include personalized therapy programs, gamification of treatment adherence, real-time monitoring, and data-driven behavioral interventions.

The Ministry of Health, Labour and Welfare (MHLW), together with other agencies, has revised policies and guidelines to facilitate wider adoption of telemedicine and online medical treatments.

In June 2023, the Basic Policy for Promoting Online Medical Treatments and Other Forms of Telemedicine was published, laying the foundation for expanded remote care and digital health services. This policy supports the deployment of digital therapeutic platforms, remote patient monitoring systems, and cloud-based patient care tools.

Report Coverage

This research report categorizes the market for the Japan digital therapeutics market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan digital therapeutics market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan digital therapeutics market.  

Driving Factors

The Japanese digital therapeutics market is driven by the rising prevalence of chronic diseases such as diabetes, obesity, and cardiovascular conditions, increasing smartphone and wearable device adoption, and growing patient awareness of digital health solutions. Integration with remote monitoring systems, telehealth platforms, and personalized therapy programs further fuels market growth. Additionally, government initiatives promoting telemedicine and digital health, coupled with hospital and employer adoption of digital therapeutic solutions, significantly enhance market expansion across Japan.

Restraining Factors

The Japanese digital therapeutics market is restrained by high development and implementation costs, regulatory complexities, and limited awareness among certain patient populations. Integration challenges with traditional healthcare systems and concerns regarding data privacy and security also limit faster adoption.

Market Segmentation

The Japan Digital Therapeutics Market share is categorized by Application and End Use.

• The Diabetes segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japanese digital therapeutics market is segmented by application into diabetes, obesity, cardiovascular disease (CVD), CNS disease, respiratory diseases, smoking cessation, and others. Among these, the Diabetes segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. This segment is growing due to increasing prevalence, clinical validation, and integration with continuous glucose monitoring. The Obesity segment is expanding rapidly with lifestyle management programs and digital interventions. CVD solutions are witnessing growth with remote cardiac rehabilitation and monitoring. CNS Disease applications, including mental health and cognitive therapy, are steadily increasing. Respiratory Diseases and Smoking Cessation solutions are gaining adoption via mobile health and telehealth platforms. Others include sleep disorders, musculoskeletal therapy, and chronic pain management.

• The Patients segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan digital therapeutics market is segmented by end use into patients, healthcare providers, healthcare payers, employers, and others. Among these, the Patients segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. This segment is growing due to mobile health adoption, remote care solutions, and personalized therapy access. Healthcare Providers are implementing digital therapeutics in clinics and hospitals to complement conventional treatment pathways. Healthcare Payers are leveraging digital therapeutics for cost-efficient disease management and preventive care programs. Employers adopt these solutions for workplace wellness and employee health improvement. Others include research institutions, rehabilitation centers, and specialty clinics utilizing digital therapeutics for therapy and clinical trials.

Competitive Analysis

The report offers the appropriate analysis of the key organizations/companies involved within the Japan digital therapeutics market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• CureApp Inc.
• Rakuten Medical, Inc.
• Omron Healthcare Co., Ltd.
• Otsuka Holdings Co., Ltd.
• Sony Corporation (Digital Health Division)
• Medtronic Japan
• Pear Therapeutics
• Propeller Health Japan
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities
• Consulting and Research Firms
• Venture Capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In March 2024, CureApp launched an advanced digital therapeutic platform for diabetes and obesity management in Japan, integrating remote patient monitoring and personalized treatment plans. The platform enables healthcare providers to track patient progress in real time and supports improved patient engagement and adherence to therapy.

Market Segment

This study forecasts revenue at the Japan, regional, and country levels from 2020 to 2035. Decision Advisior has segmented the Japan Digital Therapeutics Market based on the below-mentioned segments:

Japan Digital Therapeutics Market, By Application

• Diabetes
• Obesity
• CVD
• CNS Disease
• Respiratory Diseases
• Smoking Cessation
• Others

Japan Digital Therapeutics Market, By End Use

• Patients
• Healthcare Providers
• Healthcare Payers
• Employers
• Others

FAQs

Q. What is the market size of the Japan Digital Therapeutics Market in 2024?

A: The Japan Digital Therapeutics Market was valued at USD 285.2 million in 2024.

Q. What is the expected CAGR of the Japan Digital Therapeutics Market from 2025 to 2035?

A: The market is projected to grow at a CAGR of 18.03% during 2025–2035.

Q. What are the key factors driving the growth of the Japan Digital Therapeutics Market?

A: Market growth is driven by rising chronic disease prevalence, increasing adoption of mobile and web-based therapy solutions, and government support for telemedicine and digital health initiatives.

Q. Which application segment held the largest share of the Japan Digital Therapeutics Market in 2024?

A: The diabetes segment held the largest revenue share in 2024 due to rising prevalence and clinical validation of digital therapy programs.

Q. Which end-use segment dominates the Japan Digital Therapeutics Market?

A: Patients dominate the market due to increasing personal adoption of mobile health apps, remote monitoring, and digital therapeutic platforms.